VVOS

Vivos Therapeutics, Inc.

NasdaqCMUSDEQUITY DELAYED

0.30

▲ 0.02 (7.27%)

MARKET · —

Price

Open

0.28

Prev close

0.28

Day high

0.30

Day low

0.28

Volume

104.19K

Market cap

—

P/E (TTM)

—

52W range

0.26 – 5.12

Trailing performance

Price return · vs SPY

Returnvs SPY

-13.41% -12.0%

-24.04% -27.8%

-49.23% -52.3%

-81.78% -92.8%

YTD

-85.37% -97.7%

-92.81% -112.8%

-96.54% -170.7%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

0.30

-0.66% from price

SMA 20

0.35

-14.37% from price

SMA 50

0.42

-28.52% from price

SMA 100

0.64

-53.29% from price

SMA 200

1.24

-76.10% from price

EMA 12

0.31

-4.47% from price

EMA 26

0.36

-15.96% from price

EMA 50

0.44

-32.35% from price

RSI (14)

38.3

Neutral

MACD (12,26,9)

-0.04

Hist -0.00

ATR (14)

0.05

17.12% of price

Realised vol 30D

116.2%

Annualised

Bollinger upper

0.46

20, 2σ

Bollinger lower

0.23

20, 2σ

50 / 200 cross

Death

0.42 vs 1.24

Trend bias

Below 200

-76.10%

Risk profile

Daily returns · 1Y window

Beta vs SPY

0.95

Less volatile than market

Correlation to SPY

0.13

Largely independent

Realised vol 30D

116.2%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-94.1%

Peak to trough

Max drawdown 5Y

-99.8%

Peak to trough

ATR 14

0.05

17.12% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 0.30

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

VVOS · links out to the publisher

Sector Update: Healthcare Stocks Fall Late Afternoon MT Newswires · 2d ago Vivos Therapeutics Opens Nevada Sleep Treatment Center MT Newswires · 2d ago Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment GlobeNewswire · 2d ago Vivos Therapeutics Inc (VVOS) (Q2 2026) Earnings Call Highlights: Revenue Surges 35% on ... GuruFocus.com · 4d ago Vivos Therapeutics shares slide after Q2 revenue falls short of forecasts InvestorsHub · 5d ago Vivos Therapeutics, Inc. Q2 2026 Earnings Call Summary Moby · 7d ago Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates Zacks · 8d ago Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update GlobeNewswire · 8d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.